BeiGene News
-
September 19, 2022BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
-
September 19, 2022NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
-
September 10, 2022BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
-
September 7, 2022BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
-
August 23, 2022BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
-
August 15, 2022BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
- BeiGene Facts
- 2010Founded
- NASDAQ: BGNE
HKEX: 06160Listings - 8Internally Developed
Clinical Candidates - 8Marketed
Products
in China - 1Approved
Product
in the U.S. - 8,000+Global Team
Partnering
Partnerships that Extend Around the Globe
BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.
Our Patients
Our Commitment to Patients
At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.